Kristen Sullivan
About Kristen Sullivan
Kristen Sullivan is the Director of Real World Evidence Strategy at Bristol Myers Squibb, with over 15 years of experience in clinical trials and registry programs.
Current Position at Bristol Myers Squibb
Kristen Sullivan currently holds the position of Director, Real World Evidence Strategy at Bristol Myers Squibb. In this role, she develops and implements evidence strategies to leverage real-world data. Her work contributes to the strategic use of real-world evidence to support regulatory decisions and market access strategies.
Previous Roles and Experience
Before becoming Director at Bristol Myers Squibb, Kristen Sullivan served as Associate Director, Strategic Evidence Integration and Collaborations from 2019 to 2021. Prior to her roles at Bristol Myers Squibb, she held multiple positions at Celgene, including Associate Director, Registries Program Manager for 7 months in 2019, and Associate Director, Clinical Studies from 2016 to 2019, based in Kansas City, Missouri Area. She also worked as Senior Manager, Clinical Trials from 2012 to 2016 and as Manager, Clinical Trials from 2008 to 2012.
Early Career
Kristen Sullivan's early career includes positions at Pharmion as Manager, Registry Program from 2006 to 2008, and at Quintiles as Clinical Study Manager from 2005 to 2006. She began her career at GlaxoSmithKline, where she worked as Lead Clinical Research Associate from 2002 to 2005.
Educational Background
Kristen Sullivan earned an MBA with a focus on Marketing and Management from Rockhurst University. She also holds a Bachelor's degree in Biology from the University of Missouri-Columbia. Her educational background provides a strong foundation in both biological sciences and business administration.
Expertise in Clinical Trials and Registry Programs
With over 15 years of experience in the pharmaceutical industry, Kristen Sullivan has a comprehensive background in managing clinical trials and registry programs. Her expertise spans multiple leadership positions across several companies, including strategic roles at both Celgene and Bristol Myers Squibb. Her work has significantly contributed to the development and management of clinical studies and evidence strategies.